Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 12189257)

1.

Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder.

Sonawalla SB, Papakostas GI, Petersen TJ, Yeung AS, Smith MM, Sickinger AH, Gordon J, Israel JA, Tedlow JR, Lamon-Fava S, Fava M.

Psychosomatics. 2002 Jul-Aug;43(4):310-6.

PMID:
12189257
2.

Fluoxetine treatment of depressed patients with comorbid anxiety disorders.

Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, Rosenbaum JF, Fava M.

J Psychopharmacol. 2002 Sep;16(3):215-9.

PMID:
12236627
3.

Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.

Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, Worthington J, Baer L, Rosenbaum JF.

J Clin Psychopharmacol. 2002 Aug;22(4):379-87.

PMID:
12172337
4.

Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression.

Papakostas GI, Petersen T, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M.

J Clin Psychiatry. 2004 Aug;65(8):1090-5.

PMID:
15323594
5.

Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.

Papakostas GI, Petersen T, Homberger CH, Green CH, Smith J, Alpert JE, Fava M.

Ann Clin Psychiatry. 2007 Jan-Mar;19(1):5-8.

PMID:
17453655
6.

Serum cholesterol in treatment-resistant depression.

Papakostas GI, Petersen T, Sonawalla SB, Merens W, Iosifescu DV, Alpert JE, Fava M, Nierenberg AA.

Neuropsychobiology. 2003;47(3):146-51.

PMID:
12759558
7.

Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group.

Small GW, Birkett M, Meyers BS, Koran LM, Bystritsky A, Nemeroff CB.

J Am Geriatr Soc. 1996 Oct;44(10):1220-5.

PMID:
8856002
9.

Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder.

Lin CH, Lane HY, Chen CC, Juo SH, Yen CF.

Clin J Pain. 2011 Nov-Dec;27(9):805-10. doi: 10.1097/AJP.0b013e3182201849.

PMID:
21677571
10.

Predicting response to fluoxetine in geriatric patients with major depression.

Koran LM, Hamilton SH, Hertzman M, Meyers BS, Halaris AE, Tollefson GD, Downs JM, Folks DG, Jeste DV, Lazarus LW, et al.

J Clin Psychopharmacol. 1995 Dec;15(6):421-7.

PMID:
8748431
11.

Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression?

Castrogiovanni P, Blardi P, De Lalla A, Dell'Erba A, Auteri A.

Psychopharmacol Bull. 2003 Spring;37(2):102-8.

PMID:
14566218
13.

Fluoxetine once every third day in the treatment of major depressive disorder.

Tural U, Onder E.

Eur Arch Psychiatry Clin Neurosci. 2003 Dec;253(6):307-12.

PMID:
14714120
14.

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients.

Dierick M, Ravizza L, Realini R, Martin A.

Prog Neuropsychopharmacol Biol Psychiatry. 1996 Jan;20(1):57-71.

PMID:
8861177
15.
16.
17.
18.

Residual symptoms in depressed patients who respond acutely to fluoxetine.

Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ 3rd, Rosenbaum JF, Fava M.

J Clin Psychiatry. 1999 Apr;60(4):221-5.

PMID:
10221281
19.

Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.

Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME.

J Affect Disord. 2000 Aug;59(2):119-26.

PMID:
10837880
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk